Pharma, Biotech and Generics Industry News | The Pharmaletter
21 October 2024 As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 18 October 2024 An Expert View from Nick Petschek, Managing Director EMEA ...
Pharmaceutical Industry News | The Pharmaletter
Oct 9, 2024 · CinFina Pharma, a CinRx portfolio developing a portfolio of treatment options for obesity, has presented positive top-line interim results from its Phase I single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109. 4 November 2024.
Pharma and Biotech News | The Pharmaletter
Nov 1, 2024 · The week in pharma: action, reaction and insight – week to November 1. US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co.
FDA drug regulation and approval news | The Pharmaletter
Nov 4, 2024 · Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024.
Pharma and Biotech News in Brief | The Pharmaletter
Oct 14, 2024 · Sanofi outpaces expectations in third quarter 2024. Sanofi reported 15.7% sales growth for the third quarter of the year, reaching 13.4 billion euros ($14.2 billion), with adjusted earnings per share (EPS) rising by 12.2% to 2.86 euros, surpassing many forecasts. 25 October 2024. Biotechnology.
Pharma & Biotech Industry Analysis, from Thought Leaders
Sep 30, 2024 · F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic.
AstraZeneca exceeds estimates and ups guidance | The Pharmaletter
14 hours ago · AstraZeneca exceeds estimates and ups guidance. Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) beat analyst expectations with its third-quarter revenue and earnings figures. The Cambridge-based firm reported revenue of $12.95 billion for the quarter, up 18% on the same period of 2023, and core earnings per share (EPS) of $2.08, up 20%.
Pharmaceutical Generics Industry News | The Pharmaletter
Sep 9, 2024 · API price plunge brings forth spectre of Chinese predatory pricing. A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024. More Generics News >.
Pharma Pricing, Policy and Regulatory News | The Pharmaletter
Oct 22, 2024 · The week in pharma: action, reaction and insight – week to November 1. US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co.
About The Pharma Letter | The Pharmaletter
5 days ago · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.